Evidence map›Paper›PMID 42144897›Full record

ArticleBiotechnology progress

Multivariate phase-dependent optimization of bioprocesses boosts performance and quality-Why timing (of exposure) matters.

Samuel Kienzle, Lisa Junghans, Anja Wittmann, Stefan Wieschalka, Ralf Takors, Nicole Erika Radde, Beate Presser, Verena Nold

Abstract read
In one paragraph

Article in Biotechnology progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Samuel KienzleGlobal Development CMC Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany.ORCID 0000-0002-6816-0401
Lisa JunghansGlobal Development CMC Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany.
Anja WittmannGlobal Development CMC Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany.
Stefan WieschalkaGlobal Development CMC Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany.
Ralf TakorsInstitute of Biochemical Engineering, University of Stuttgart, Stuttgart, Germany.
Nicole Erika RaddeInstitute for Stochastics and Applications, University of Stuttgart, Stuttgart, Germany.
Beate PresserGlobal Development CMC Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany.
Verena NoldComputational Innovation, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Applying a single parameter set to describe complex mammalian kinetics often is too simplistic, as it fails to capture sensitive cell-to-environment interactions that may be exploited to optimize production performance. To resolve this time dependency, intra-experimental parameter shifts as part of design of dynamic experiments (DoDE) can be performed to study mammalian growth and production kinetics in fed-batch processes. This enables growth phase-dependent optimization, aligned with cellular requirements. Here, we provide a comprehensive, head-to-head comparison of our phase-dependent optimization approach with intra-experimental shifts of process parameters to a static optimization that retains parameter settings through the entire bioprocess. Showcasing a monoclonal antibody production process development scenario, the study examines growth phase-dependent effects of temperature (T) and dissolved oxygen (DO) together with time-invariant parameters for feed and seeding cell density. While the static optimization suggests settings near the center of the design space, phase-dependent optimization finds an optimum by shifting T and DO between the exponential growth, transition, and production phases. Overall, the phase-wise optimized process gives an experimentally validated ~30% increase in product titer while maintaining comparable product quality. Furthermore, the approach breaks the correlation between product titer and acidic charged variants: both depend on T but at different timeframes. Additionally, DoDE uncovers a crucial interaction between T and DO, with low T and high DO during the exponential growth phase, leading to strong lactate accumulation. The data demonstrate the advantages of phase-dependent optimization enabled by DoDE. The results may serve as a good practice example for follow-up research.

Indexed as

Antibodies, MonoclonalBatch Cell Culture TechniquesAnimalsBioreactorsCHO CellsCricetulusKineticsOxygenTemperatureAntibodies, MonoclonalOxygendesign of dynamic experimentsfed‐batch cultivationintra‐experimental parameter shiftsphase‐dependent optimizationprocess developmentquality by designtime‐variant kinetics

Identifiers

PMID42144897
PMCPMC13441397

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.